Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension The TRINITY Randomized, Double-Blind, 12-Week, Parallel-Group Study

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 12; no. 4; pp. 233 - 243
• Main Authors: Chrysant, Steven G., Littlejohn, Thomas, Izzo, Joseph L., Kereiakes, Dean J., Oparil, Suzanne, Melino, Michael, Lee, James, Fernandez, Victor, Heyrman, Reinilde
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2012
• Subjects: Adult; African Continental Ancestry Group; Aged; Amlodipine - administration & dosage; Amlodipine - adverse effects; Antihypertensive Agents - administration & dosage; Cardiology; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide - administration & dosage; Hydrochlorothiazide - adverse effects; Hypertension - drug therapy; Hypertension - ethnology; Imidazoles - administration & dosage; Imidazoles - adverse effects; Male; Medicine; Medicine & Public Health; Middle Aged; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Tetrazoles - administration & dosage; Tetrazoles - adverse effects; HCTZ; Black Patient; Severe Hypertension; Blood Pressure Goal; Olmesartan Medoxomil
• ISSN: 1175-3277; 1179-187X
• DOI: 10.1007/BF03261832

Background Although awareness of hypertension in Black patients has increased, blood pressure (BP) is frequently inadequately controlled. Objective This prespecified subgroup analysis of the TRINITY study evaluated the efficacy and safety of olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment compared with the component dual-combination treatments in Black and non-Black study participants. Study Design TRINITY was a 12-week, randomized, double-blind, parallel-group evaluation. The first patient was enrolled in May 2008 and the last patient completed the study in February 2009. The study consisted of a 3-week washout period for participants receiving antihypertensive therapy and a 12-week double-blind treatment period. For the treatment phase, all study participants were stratified by age, race, and diabetes mellitus status and randomized to a treatment sequence that led to their final treatment assignment, which they received from weeks 4 to 12 (OM 40 mg/AML 10 mg/HCTZ 25 mg, OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, or AML 10 mg/HCTZ 25 mg). In the first 2 weeks of the double-blind treatment period, all participants received either dual-combination treatment or placebo. Participants assigned to dual-combination treatment continued treatment until week 4, and participants receiving placebo were switched at week 2 to receive one of the dual-combination treatments until week 4. At week 4, participants either continued dual-combination treatment or randomly received triple-combination treatment until week 12. Setting 317 clinical sites in the USA and Puerto Rico were included in the study. Patients Study participants eligible for randomization (N = 2492) were ≥18 years of age with mean seated blood pressure (SeBP) ≥140/100 mmHg or ≥160/90 mmHg (off antihypertensive medication). Intervention The intervention was with dual- or triple-combination antihypertensive treatment: OM 40 mg/AML 10 mg/HCTZ 25 mg, OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, or AML 10 mg/HCTZ 25 mg. Main Outcome Measure The primary efficacy variable was the change in least squares (LS) mean seated diastolic BP (SeDBP) from baseline to week 12. Secondary efficacy variables included the LS mean change in seated systolic BP (SeSBP), percentage of study participants reaching BP goal, and safety parameters. >Results In both Black and non-Black participants, triple-combination treatment resulted in significant and similar mean reductions in SeDBP and SeSBP (p≤0.0001 vs each dual-combination treatment) with a greater proportion of participants reaching BP goal compared with dual-combination treatments, regardless of race. Most treatment-emergent adverse events were mild or moderate in severity and no new safety concerns were identified. Conclusion Triple-combination treatment provided greater BP reductions than dual-combination treatments regardless of race. Clinical Trial Registration Registered at ClinicalTrials.gov as NCT00649389.